Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep111 | Adrenal and Cardiovascular Endocrinology | ECE2023

Coexistence of adrenocorticotropic hormone-dependent Cushing’s syndrome and papillary thyroid carcinoma

Sliman Chayma Bel Hadj , Najla Bchir , Chehaider Cyrine , Benchhida Annam , Chadia Zouaoui , Ouertani Haroun

Introduction: Papillary thyroid carcinoma is one of the most prevalent endocrine tumors. Adrenocorticotropic hormone (ACTH) dependent Cushing’s syndrome is a rare disease. We report a rare case of coexistence of papillary thyroid carcinoma and ACTH-dependent Cushing’s syndrome.Observation: A 59-year-old man, was admitted to our endocrinology department for exploration of bilateral adrenal incidentalomas discovered in an abdominal CT scan done i...

ea0090ep118 | Adrenal and Cardiovascular Endocrinology | ECE2023

Coexistence of Gilbert’s disease, thyroid nodule, parathyroid adenoma, and Cushing’s syndrome: A rare presentation

Sliman Chayma Bel Hadj , Najla Bchir , Dorraelguiche Dorra , Benchhida Annam , Chadia Zouaoui , Ouertani Haroun

Introduction: Gilbert syndrome is a common autosomal dominant hereditary condition characterized by intermittent unconjugated hyperbilirubinemia in the absence of hepatocellular disease or hemolysis. Multiple endocrine neoplasia (MEN) is defined by the association of a neoplasia or hyperplasia of at least two endocrine glands and caused by multiple mutations. Rare cases of atypical MEN were reported in the literature. We report the case of a patient with a history of gilbert&#...

ea0090ep439 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Effect of Liraglutide on glycemic control in type 2 diabetic patients

Chadia Zouaoui , Sliman Chayma Bel Hadj , Myriam Baltagi , Najla Bchir , Benchhida Annam , Ouertani Haroun

Introduction: Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA), approved for management of type 2 diabetes (T2D).Aim: The aim of our study is to evaluate the effectiveness of Liraglutide in controlling blood glucose levels over a period of 6 to 12 months in Tunisian type 2 diabetic patients.Methods: We conducted a prospective descriptive study at the endocrinology-nutrition department of the military hospital of...

ea0090ep540 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Assessment of metabolic profile in type 2 diabetic patients after 12 weeks of treatment by Liraglutide

Chadia Zouaoui , Sliman Chayma Bel Hadj , Najla Bchir , Myriam Baltagi , Benchhida Annam , Ouertani Haroun

Introduction: Liraglutide has been shown to have a positive effect on the glycemic and lipidic profile of diabetic patients. We aimed to assess the metabolic profile in type 2 diabetic patients after 12 weeks of treatment by LiraglutideMethods: This is a prospective study performed at the endocrinology department of the Military Hospital of Tunis. We recruited 22 patients with type 2 diabetes (T2D) treated with insulin and/or oral antidiabetics. Liraglut...

ea0090ep570 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Assessment of anthropometric parameters in type 2 diabetic patients on Liraglutide

Chadia Zouaoui , Hadj Sliman Chayma Bel , Najla Bchir , Gharbi Youssef , Benchhida Annam , Ouertani Haroun

Introduction: Glycemic control and weight management are crucial considerations in the treatment of type 2 diabetes (T2D). Liraglutide, an incretin-based therapy, has been demonstrated to not only effectively maintain glycemic control but also promote weight loss in type 2 diabetic patients. Our study aims to evaluate the impact of Liraglutide on body weight and body composition parameters in patients with T2D.Methods: This is a prospective study, carrie...

ea0090ep571 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Reasons of Liraglutide discontinuation in Tunisian type 2 diabetic patients

Chadia Zouaoui , Hadj Sliman Chayma Bel , Najla Bchir , Chanez Kalboussi , Eya Sassi , benchhida annam , Ouertani Haroun

Introduction: Liraglutide is an anti-diabetic drug that has been shown to be effective for glycemic control and weight loss. However, factors such as unavailability, high cost, and side effects may make it challenging for patients to continue treatment. Our study aims to identify these barriers to treatment adherence and to understand the factors contributing to the discontinuation of Liraglutide therapy in Tunisian patients with type 2 diabetes (T2D).Me...

ea0090ep781 | Pituitary and Neuroendocrinology | ECE2023

Macroprolactinoma in a patient with Schizophrenia: which illness should be treated first?

Chayma Bel Hadj Sliman , Najla Bchir , Myriam Baltagi , Benchhida Annam , Dorraelguiche Dorra , Chadia Zouaoui , Ouertani Haroun

Introduction: Prolactinomas are the most common of functional pituitary tumors. Dopamine agonists are the first line treatment of prolactinomas but have antagonistic effect with antipsychotics (dopamine receptor blockers) used in schizophrenia. The association between these two illnesses is a medical challenge, as the treatment of one disease can exacerbate the symptoms of the other one.Clinical case: We report the case of a 72-year old man, newly diagno...

ea0090ep821 | Pituitary and Neuroendocrinology | ECE2023

Comparison between insulin tolerance test and clonidine stimulation test in the exploration of growth hormone deficiency

Abadlia Salma , Najla Bchir , Zouaoui Chadia , Ben Yamna Hadami , Ben Chehida Anaam , Ouertani Haroun

Introduction: Growth hormone deficiency (GHD) is a rare cause of delay of growth. However, it is primordial to screen for it since its presence leads to a specific treatment which improves statural prognosis. GHD should be confirmed through stimulation tests such as Insulin Tolerance test (ITT) or Clonidine Stimulation Test (CST). The objective of our study was to compare these two diagnostic tools.Methods: We conducted a retrospective study in the endoc...

ea0090ep860 | Pituitary and Neuroendocrinology | ECE2023

GH deficiency caused by a macroprolactinoma: difficulty of management

Dorraelguiche Dorra , Najla Bchir , Ben Chehida Annaam , Myriam Baltagi , Chadia Zouaoui , Ouertani Haroun

Introduction: The use of GH treatment in patients with macroadenomas and GH deficiency is of concern to the clinician due to the theoretical stimulation of tumor regrowth by GH substitution. We report the case of an 18-year-old adolescent with a macroprolactinoma causing delayed stature and puberty.Observation : We report the case of an 18-year-oldadolescent who consulted for gynecomastia with delayed stature and puberty. Physical examination displayed a...

ea0090ep887 | Pituitary and Neuroendocrinology | ECE2023

Non-secreting pituitary adenomas: clinical, biological, radiological and therapeutic aspects: a review of 17 cases

Rekaya Zeineb , Bchir Najla , Ben Zaied Fatma , Ben Chehida Anaam , Chadia Zouaoui , Ouertani Haroun

Non-secreting pituitary adenomas (NSPA) are relatively rare benign tumors their prognosis depends essentially on their endocrine and ophthalmological repercussions the aim of our study is to outline their clinical, biological, radiological aspects, and the therapeutic choice.Methods: Retrospective study of 17 patients with non secreting pituitary adenomas.Results: We identified 17 patients with NSPA split into 12 women and 5 men wi...